OA11749A - Tricyclic inhibitors of poly(adp-ribose)polymerases. - Google Patents
Tricyclic inhibitors of poly(adp-ribose)polymerases. Download PDFInfo
- Publication number
- OA11749A OA11749A OA1200100183A OA1200100183A OA11749A OA 11749 A OA11749 A OA 11749A OA 1200100183 A OA1200100183 A OA 1200100183A OA 1200100183 A OA1200100183 A OA 1200100183A OA 11749 A OA11749 A OA 11749A
- Authority
- OA
- OAPI
- Prior art keywords
- mmol
- compound
- tetrahydro
- alkyl
- azepino
- Prior art date
Links
- 0 *C(CC1)=CC=C1c([n]c1ccc2)c(CCN3)c1c2C3=O Chemical compound *C(CC1)=CC=C1c([n]c1ccc2)c(CCN3)c1c2C3=O 0.000 description 6
- DFYMTPQQVYYQCH-UHFFFAOYSA-N CC(C1C(NCC2)=O)C=Cc3c1c2c(C#Cc1cc(N)ccc1)[nH]3 Chemical compound CC(C1C(NCC2)=O)C=Cc3c1c2c(C#Cc1cc(N)ccc1)[nH]3 DFYMTPQQVYYQCH-UHFFFAOYSA-N 0.000 description 1
- OZHSUXVBXCRJCE-UHFFFAOYSA-N CC(Nc(ccc(F)c1)c1-c([nH]c1ccc2)c(CCN3)c1c2C3=O)=O Chemical compound CC(Nc(ccc(F)c1)c1-c([nH]c1ccc2)c(CCN3)c1c2C3=O)=O OZHSUXVBXCRJCE-UHFFFAOYSA-N 0.000 description 1
- SNHDYFZUKUJZND-UHFFFAOYSA-N CC(c1cccc2c1c(CCN)c(-c1ccc(CN(C)C)cc1)[nH]2)=O Chemical compound CC(c1cccc2c1c(CCN)c(-c1ccc(CN(C)C)cc1)[nH]2)=O SNHDYFZUKUJZND-UHFFFAOYSA-N 0.000 description 1
- FCYQYEPRWPMDBZ-UHFFFAOYSA-N CN(C)Cc1cccc(-c([nH]c2ccc3)c(CCN4)c2c3C4=O)c1 Chemical compound CN(C)Cc1cccc(-c([nH]c2ccc3)c(CCN4)c2c3C4=O)c1 FCYQYEPRWPMDBZ-UHFFFAOYSA-N 0.000 description 1
- OZSBLJFTXFBONL-UHFFFAOYSA-N CNC(c1c(CCNC(C2CC=C3)=O)c2c3[nH]1)=O Chemical compound CNC(c1c(CCNC(C2CC=C3)=O)c2c3[nH]1)=O OZSBLJFTXFBONL-UHFFFAOYSA-N 0.000 description 1
- FJWGMKAOYDKDMW-UHFFFAOYSA-N COC1C=CC=CC1C(C1CCNC2=O)Nc3c1c2ccc3 Chemical compound COC1C=CC=CC1C(C1CCNC2=O)Nc3c1c2ccc3 FJWGMKAOYDKDMW-UHFFFAOYSA-N 0.000 description 1
- ZHVHKPUNTSCCLV-UHFFFAOYSA-N CSC1C=CC=CC1C(C1CCNC2=O)Nc3c1c2ccc3 Chemical compound CSC1C=CC=CC1C(C1CCNC2=O)Nc3c1c2ccc3 ZHVHKPUNTSCCLV-UHFFFAOYSA-N 0.000 description 1
- JBIJEHLYXDQFGI-UHFFFAOYSA-N C[n](cc1CCNC2=O)c3c1c2ccc3 Chemical compound C[n](cc1CCNC2=O)c3c1c2ccc3 JBIJEHLYXDQFGI-UHFFFAOYSA-N 0.000 description 1
- YHXXMQXRWSPCEG-UHFFFAOYSA-N C[n]1c(-c2ccc(C=O)cc2)c(CN2)c3c1cccc3C2=O Chemical compound C[n]1c(-c2ccc(C=O)cc2)c(CN2)c3c1cccc3C2=O YHXXMQXRWSPCEG-UHFFFAOYSA-N 0.000 description 1
- JBBHEUQXGHYOGK-UHFFFAOYSA-N C[n]1c(-c2ccccc2)c(CCN2C)c3c1cccc3C2=O Chemical compound C[n]1c(-c2ccccc2)c(CCN2C)c3c1cccc3C2=O JBBHEUQXGHYOGK-UHFFFAOYSA-N 0.000 description 1
- INSHCQILZKMTQZ-UHFFFAOYSA-N C[n]1c(Br)c(CN2)c3c1cccc3C2=O Chemical compound C[n]1c(Br)c(CN2)c3c1cccc3C2=O INSHCQILZKMTQZ-UHFFFAOYSA-N 0.000 description 1
- JFLSKPUGPSYALU-UHFFFAOYSA-N NOC(c1c(CCNC(C2CC=C3)=O)c2c3[nH]1)=O Chemical compound NOC(c1c(CCNC(C2CC=C3)=O)c2c3[nH]1)=O JFLSKPUGPSYALU-UHFFFAOYSA-N 0.000 description 1
- ZRRIVOUCCUFNDH-UHFFFAOYSA-N O=C(c1cccc([nH]2)c11)NCCc1c2Br Chemical compound O=C(c1cccc([nH]2)c11)NCCc1c2Br ZRRIVOUCCUFNDH-UHFFFAOYSA-N 0.000 description 1
- INPYZUKENVJTPY-UHFFFAOYSA-N O=C1N=CCc2c(-c(cc3)ccc3Cl)[nH]c3c2c1ccc3 Chemical compound O=C1N=CCc2c(-c(cc3)ccc3Cl)[nH]c3c2c1ccc3 INPYZUKENVJTPY-UHFFFAOYSA-N 0.000 description 1
- USOHCFXAXZIYAR-UHFFFAOYSA-N O=C1NCCC2c3c1cccc3NC2C1=CSCC1 Chemical compound O=C1NCCC2c3c1cccc3NC2C1=CSCC1 USOHCFXAXZIYAR-UHFFFAOYSA-N 0.000 description 1
- LEQTVGHPTNSWLT-UHFFFAOYSA-N O=C1NCCc2c(-c(cc3)cc4c3[nH]cc4)[nH]c3c2c1ccc3 Chemical compound O=C1NCCc2c(-c(cc3)cc4c3[nH]cc4)[nH]c3c2c1ccc3 LEQTVGHPTNSWLT-UHFFFAOYSA-N 0.000 description 1
- VNSKVRAHQYBTJT-UHFFFAOYSA-N O=C1NCCc2c(-c3ccc[nH]3)[nH]c3cccc1c23 Chemical compound O=C1NCCc2c(-c3ccc[nH]3)[nH]c3cccc1c23 VNSKVRAHQYBTJT-UHFFFAOYSA-N 0.000 description 1
- KQNQAZATUCCCPG-UHFFFAOYSA-N O=C1NCCc2c(-c3ccc[s]3)[nH]c3c2c1ccc3 Chemical compound O=C1NCCc2c(-c3ccc[s]3)[nH]c3c2c1ccc3 KQNQAZATUCCCPG-UHFFFAOYSA-N 0.000 description 1
- AMXUETXVQWSXKX-UHFFFAOYSA-N O=C1NCCc2c(-c3cccc(-c4ccccc4)c3)[nH]c3c2C1CC=C3 Chemical compound O=C1NCCc2c(-c3cccc(-c4ccccc4)c3)[nH]c3c2C1CC=C3 AMXUETXVQWSXKX-UHFFFAOYSA-N 0.000 description 1
- CMVVSYUUFABRBC-UHFFFAOYSA-N O=C1NCCc2c(-c3ccccc3)[nH]c3c2c1ccc3 Chemical compound O=C1NCCc2c(-c3ccccc3)[nH]c3c2c1ccc3 CMVVSYUUFABRBC-UHFFFAOYSA-N 0.000 description 1
- IYMQVKUQADGSQJ-UHFFFAOYSA-N O=C1NCCc2c(-c3ccncc3)[nH]c3cccc1c23 Chemical compound O=C1NCCc2c(-c3ccncc3)[nH]c3cccc1c23 IYMQVKUQADGSQJ-UHFFFAOYSA-N 0.000 description 1
- BHBVHHZAFNDPRL-UHFFFAOYSA-N O=C1NCCc2c(C#Cc3ccccc3)[nH]c3c2c1ccc3 Chemical compound O=C1NCCc2c(C#Cc3ccccc3)[nH]c3c2c1ccc3 BHBVHHZAFNDPRL-UHFFFAOYSA-N 0.000 description 1
- RQSDPFPPPFHEQV-UHFFFAOYSA-N OC(C1Nc2cccc3c2C1CCNC3=O)=O Chemical compound OC(C1Nc2cccc3c2C1CCNC3=O)=O RQSDPFPPPFHEQV-UHFFFAOYSA-N 0.000 description 1
- YWOBNNJZEWLGBH-UHFFFAOYSA-N OC(c(cc1)ccc1-c([nH]c1ccc2)c(CCN3)c1c2C3=O)=O Chemical compound OC(c(cc1)ccc1-c([nH]c1ccc2)c(CCN3)c1c2C3=O)=O YWOBNNJZEWLGBH-UHFFFAOYSA-N 0.000 description 1
- HRURBEXWPIVDNB-UHFFFAOYSA-N OCc1cc(-c([nH]c2ccc3)c(CCN4)c2c3C4=O)ccc1 Chemical compound OCc1cc(-c([nH]c2ccc3)c(CCN4)c2c3C4=O)ccc1 HRURBEXWPIVDNB-UHFFFAOYSA-N 0.000 description 1
- ZTSDSUFWOPZCIG-UHFFFAOYSA-N [O-][N+](c1cc(-c([nH]c2ccc3)c(CCN4)c2c3C4=O)ccc1)=O Chemical compound [O-][N+](c1cc(-c([nH]c2ccc3)c(CCN4)c2c3C4=O)ccc1)=O ZTSDSUFWOPZCIG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11543199P | 1999-01-11 | 1999-01-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA11749A true OA11749A (en) | 2005-07-19 |
Family
ID=22361361
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA1200100183A OA11749A (en) | 1999-01-11 | 2000-01-10 | Tricyclic inhibitors of poly(adp-ribose)polymerases. |
OA1200200262A OA12185A (en) | 1999-01-11 | 2002-08-28 | Tricyclic inhibitors of poly(adp-ribose)polymerases. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA1200200262A OA12185A (en) | 1999-01-11 | 2002-08-28 | Tricyclic inhibitors of poly(adp-ribose)polymerases. |
Country Status (40)
Country | Link |
---|---|
US (4) | US6495541B1 (de) |
EP (1) | EP1140936B1 (de) |
JP (1) | JP4093448B2 (de) |
KR (1) | KR100632079B1 (de) |
CN (1) | CN100418967C (de) |
AP (1) | AP1538A (de) |
AT (1) | ATE261963T1 (de) |
AU (1) | AU781711B2 (de) |
BG (1) | BG65210B1 (de) |
BR (1) | BRPI0008614B8 (de) |
CA (1) | CA2360003C (de) |
CZ (1) | CZ302941B6 (de) |
DE (1) | DE60009033T2 (de) |
DK (1) | DK1140936T3 (de) |
EA (1) | EA004989B1 (de) |
EE (1) | EE05006B1 (de) |
ES (1) | ES2218110T3 (de) |
GE (1) | GEP20033055B (de) |
HK (1) | HK1040992A1 (de) |
HR (1) | HRP20010573B1 (de) |
HU (1) | HU229875B1 (de) |
ID (1) | ID30138A (de) |
IL (2) | IL144112A0 (de) |
IS (1) | IS5995A (de) |
LT (1) | LT4936B (de) |
LV (1) | LV12770B (de) |
MX (1) | MXPA01007001A (de) |
NO (1) | NO320343B1 (de) |
NZ (1) | NZ512731A (de) |
OA (2) | OA11749A (de) |
PL (1) | PL210415B1 (de) |
PT (1) | PT1140936E (de) |
RO (1) | RO121778B1 (de) |
RS (1) | RS50031B (de) |
SI (1) | SI20691B (de) |
SK (1) | SK287338B6 (de) |
TR (1) | TR200102005T2 (de) |
UA (1) | UA75034C2 (de) |
WO (1) | WO2000042040A1 (de) |
ZA (1) | ZA200105399B (de) |
Families Citing this family (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0104917A3 (en) * | 1999-09-28 | 2002-12-28 | Basf Ag | Azepinoindole derivatives, the production and use thereof |
US6589725B1 (en) | 1999-10-25 | 2003-07-08 | Rigel Pharmaceuticals, Inc. | Tankyrase H, compositions involved in the cell cycle and methods of use |
US6531464B1 (en) | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
US6476048B1 (en) | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
PT1268407E (pt) * | 2000-03-20 | 2004-11-30 | N Gene Res Lab Inc | Derivados de amidoxima de acido propenocarboxilico, um processo para a sua preparacao e composicoes farmaceuticas contendo os mesmos |
US6534651B2 (en) | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
JP4323802B2 (ja) * | 2000-12-01 | 2009-09-02 | エムジーアイ・ジーピー・インコーポレーテッド | 化合物およびその使用 |
JP2004528376A (ja) | 2001-05-08 | 2004-09-16 | クドス ファーマシューティカルズ リミテッド | Parp阻害薬としてのイソキノリノン誘導体 |
NZ531245A (en) | 2001-08-15 | 2005-09-30 | Icos Corp | 2H-phthalazin-1-ones and methods for use thereof |
US20030096833A1 (en) | 2001-08-31 | 2003-05-22 | Jagtap Prakash G. | Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof |
US6956035B2 (en) | 2001-08-31 | 2005-10-18 | Inotek Pharmaceuticals Corporation | Isoquinoline derivatives and methods of use thereof |
WO2003051879A1 (en) * | 2001-12-14 | 2003-06-26 | Altana Pharma Ag | Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors |
US7196085B2 (en) | 2002-04-30 | 2007-03-27 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
ES2309484T3 (es) * | 2003-01-09 | 2008-12-16 | Pfizer Inc. | Derivados de diazepinoindol como inhibidores de quinasa. |
JP2007501857A (ja) | 2003-02-28 | 2007-02-01 | イノテック ファーマシューティカルズ コーポレーション | 四環系ベンズアミド誘導体およびその使用方法 |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
JP2006522088A (ja) * | 2003-03-31 | 2006-09-28 | ファイザー・インク | ポリ(adp−リボース)ポリメラーゼの三環系阻害剤の塩 |
MXPA05012812A (es) * | 2003-05-28 | 2006-02-28 | Guilford Pharm Inc | Compuestos, metodos y composiciones farmaceuticas para inhibir poli(adenosina-5'-difosfo-ribosa)polimerasa(parp). |
ES2339663T3 (es) * | 2003-07-25 | 2010-05-24 | Cancer Research Technology Limited | Inhibidores de parp triciclicos. |
GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
ATE521341T1 (de) | 2003-12-01 | 2011-09-15 | Kudos Pharm Ltd | Dna-schäden-reparatur-hemmer zur behandlung von krebs |
KR20060125909A (ko) | 2004-02-26 | 2006-12-06 | 이노텍 파마슈티컬스 코포레이션 | 이소퀴놀린 유도체 및 이의 사용 방법 |
EP1793830A2 (de) * | 2004-09-22 | 2007-06-13 | Pfizer, Inc. | Therapeutische kombinationen mit poly(adp-ribose)-polymerase-inhibitor |
PL1794163T3 (pl) * | 2004-09-22 | 2010-06-30 | Pfizer | Sposób wytwarzania inhibitorów poli(adp-rybozo)polimerazy |
EP1799685B1 (de) * | 2004-09-22 | 2012-03-28 | Pfizer Inc. | Polymorphe formen des phosphatsalzes von 8-fluor-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on |
CN101133061B (zh) * | 2004-09-22 | 2011-09-07 | 辉瑞有限公司 | 8-氟-2-{4-[(甲基氨基)甲基]苯基}-1,3,4,5-四氢-6H-氮杂卓并[5,4,3-cd]吲哚-6-酮的磷酸盐的多晶型物和非晶物 |
AU2006206512B2 (en) | 2005-01-19 | 2012-09-13 | Eisai Inc. | Diazabenzo(de)anthracen-3-one compounds and methods for inhibiting PARP |
KR20070116011A (ko) | 2005-02-25 | 2007-12-06 | 이노텍 파마슈티컬스 코포레이션 | 테트라사이클릭 아미노 및 카복사미도 화합물 및 이의 이용방법 |
US7402596B2 (en) | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
DE102005022111A1 (de) * | 2005-05-12 | 2006-11-16 | Siemens Ag | Verfahren zum Datenaustausch |
WO2006137510A1 (ja) * | 2005-06-24 | 2006-12-28 | Ono Pharmaceutical Co., Ltd. | 脳血管障害時における出血低減剤 |
JP5132554B2 (ja) | 2005-07-14 | 2013-01-30 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Tpo模倣剤としてのヘテロ四環化合物 |
RU2447889C2 (ru) | 2005-07-18 | 2012-04-20 | Бипар Сайенсиз, Инк. | Способ лечения рака (варианты) |
RU2008110955A (ru) | 2005-08-24 | 2009-09-27 | Инотек Фармасьютикалз Корпорейшн (Us) | Инденоизохинолиноновые аналоги и способы их применения |
GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
EP2329818A1 (de) * | 2006-01-17 | 2011-06-08 | Abbott Laboratories | Kombinationstherapie mit PARP Inhibitoren |
TWI464148B (zh) | 2006-03-16 | 2014-12-11 | Evotec Us Inc | 作為p2x7調節劑之雙環雜芳基化合物與其用途 |
US20080262062A1 (en) * | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
AU2007292306A1 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof |
WO2008030883A2 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
WO2008106619A2 (en) | 2007-02-28 | 2008-09-04 | Inotek Pharmaceuticals Corporation | Indenoisoquinolinone analogs and methods of use thereof |
WO2008154129A1 (en) * | 2007-06-08 | 2008-12-18 | Bausch & Lomb Incorporated | Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye |
US7981890B2 (en) | 2007-09-14 | 2011-07-19 | Astrazeneca Ab | Phthalazinone derivatives |
WO2009046205A1 (en) | 2007-10-03 | 2009-04-09 | Eisai Research Institute | Parp inhibitor compounds, compositions and methods of use |
EP2217227B1 (de) | 2007-11-12 | 2013-08-21 | BiPar Sciences, Inc. | Behandlung von brustkrebs mit 4-iodo-3-nitrobenzamid in kombination mit antitumoralen mitteln |
UY31603A1 (es) | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
GB0804755D0 (en) | 2008-03-14 | 2008-04-16 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
HRP20161154T4 (hr) | 2008-10-07 | 2023-09-29 | Kudos Pharmaceuticals Limited | Farmaceutska formulacija 514 |
WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
KR100986820B1 (ko) * | 2010-01-27 | 2010-10-12 | (주)에코베이스 | 막힘방지형 고효율 산기장치 및 이를 이용한 수질정화장치 |
PL2534153T3 (pl) * | 2010-02-12 | 2017-08-31 | Pfizer Inc. | Sole i polimorfy 8-fluoro-2-{4-[(metyloamino}metylo]fenylo}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-onu |
EP2646428B1 (de) | 2010-12-02 | 2016-06-01 | Shanghai De Novo Pharmatech Co Ltd. | Herstellungsverfahren für heterocyclische derivate und ihre medizinische verwendung |
PT2797921T (pt) * | 2011-12-31 | 2017-11-14 | Beigene Ltd | Dihidrodiazepinocarbazolonas tetra ou pentacíclicas fundidas como inibidoras de parp |
CN106083849A (zh) | 2011-12-31 | 2016-11-09 | 百济神州有限公司 | 作为parp抑制剂的稠合的四元或五元环吡啶并酞嗪酮类化合物 |
JP6223995B2 (ja) | 2012-11-08 | 2017-11-01 | 日本化薬株式会社 | カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途 |
CN106458935B (zh) | 2014-01-05 | 2019-05-28 | 华盛顿大学 | 用于聚(adp-核糖)聚合酶-1(parp-1)的放射性标记示踪物,其方法和用途 |
CN103772395B (zh) * | 2014-01-23 | 2016-05-11 | 中国药科大学 | 一类具有parp抑制活性的化合物、其制备方法及用途 |
ES2733847T3 (es) | 2014-06-17 | 2019-12-03 | Vertex Pharma | Método para tratar cáncer usando una combinación de inhibidores de CHK1 y ATR |
EP3182975A4 (de) | 2014-08-22 | 2018-04-18 | Clovis Oncology, Inc. | Hochdosierte rucaparibtabletten |
CN105607772B (zh) * | 2014-11-13 | 2020-11-03 | 现代自动车株式会社 | 触摸输入装置以及包括该装置的车辆 |
TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
JP6871169B2 (ja) | 2015-03-02 | 2021-05-12 | シナイ ヘルス システム | 相同組換え因子 |
EP3594343B1 (de) | 2015-07-23 | 2021-04-21 | Institut Curie | Verwendung einer kombination aus dbait-molekül und parp-inhibitoren zur behandlung von krebs |
KR20180041748A (ko) | 2015-08-25 | 2018-04-24 | 베이진 엘티디 | Parp 억제제, 결정형의 제조방법 및 이의 용도 |
WO2017059357A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
CN107286166B (zh) * | 2016-04-11 | 2020-03-31 | 上海勋和医药科技有限公司 | 取代1,3,4,5-四氢-6h-吡咯并[4,3,2-ef][2]苯并氮杂-6-酮衍生物 |
WO2018022851A1 (en) | 2016-07-28 | 2018-02-01 | Mitobridge, Inc. | Methods of treating acute kidney injury |
CN110087730B (zh) | 2016-09-27 | 2023-03-28 | 百济神州(苏州)生物科技有限公司 | 使用包含parp抑制剂的组合产品治疗癌症 |
JP6541635B2 (ja) * | 2016-10-28 | 2019-07-10 | ベイジーン リミテッド | Parp阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン |
EP3534957A1 (de) | 2016-11-02 | 2019-09-11 | Immunogen, Inc. | Kombinationsbehandlung mit antikörper-wirkstoff-konjugaten und parp-hemmern |
CN106854172B (zh) * | 2016-12-11 | 2019-04-19 | 山东轩德医药科技有限公司 | 一种6-氟-1h-吲哚-4-甲酸甲酯的制备方法 |
WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
US10875870B2 (en) * | 2017-01-24 | 2020-12-29 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib and of rucaparib salts |
CN106748958B (zh) * | 2017-01-25 | 2018-12-18 | 伦俊杰 | 一种Rucaparib中间体的制备方法 |
US10899763B2 (en) | 2017-02-28 | 2021-01-26 | Beigene, Ltd. | Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, and uses thereof |
WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
CN110997068B (zh) * | 2017-05-24 | 2022-12-06 | 宾夕法尼亚大学董事会 | 用于成像和放射疗法的经放射标记的荧光parp抑制剂 |
IT201700085789A1 (it) | 2017-07-26 | 2019-01-26 | Olon Spa | Metodo per la preparazione di rucaparib ad elevata purezza |
CA3071345A1 (en) * | 2017-07-28 | 2019-01-31 | Yale University | Anticancer drugs and methods of making and using same |
CN109651376B (zh) * | 2017-10-12 | 2022-06-03 | 江苏创诺制药有限公司 | 一种氮杂卓并[5,4,3-cd]吲哚-6-酮化合物的合成方法 |
CN109651377B (zh) * | 2017-10-12 | 2020-10-20 | 成都海创药业有限公司 | 一种治疗癌症的化合物及其用途 |
JP2021501771A (ja) * | 2017-11-03 | 2021-01-21 | サンド・アクチエンゲゼルシヤフト | 三環系ポリ(adp−リボース)ポリメラーゼ阻害剤の結晶性塩 |
WO2019115000A1 (en) | 2017-12-15 | 2019-06-20 | Advitech Advisory And Technologies Sa | Process for the preparation of rucaparib and novel synthesis intermediates |
WO2019130229A1 (en) | 2017-12-28 | 2019-07-04 | Mylan Laboratories Ltd | Methods and intermediates for preparing rucaparib |
BR112020013672A2 (pt) * | 2018-01-05 | 2020-12-01 | Cybrexa 1, Inc. | compostos, composições, e métodos para tratamento de doenças que envolvem tecidos afetados por ácidos ou hipoxia |
US10442813B2 (en) | 2018-01-30 | 2019-10-15 | RK Pharma Solutions LLC | Polymorphs of rucaparib camsylate and methods of making same |
CN110229162B (zh) * | 2018-03-05 | 2020-08-11 | 新发药业有限公司 | 一种瑞卡帕布的简便制备方法 |
JP2021515580A (ja) | 2018-03-13 | 2021-06-24 | オンクセオOnxeo | がんの治療における獲得耐性に対抗するdbait分子 |
CN110272419A (zh) * | 2018-03-14 | 2019-09-24 | 上海艾力斯医药科技有限公司 | 二氢吡啶并酞嗪酮衍生物、其制备方法及应用 |
WO2019207596A1 (en) | 2018-04-25 | 2019-10-31 | Mylan Laboratories Limited | Novel crystalline forms of rucaparib (s)-camsylate salt and rucaparib free base |
CN108743557A (zh) * | 2018-06-27 | 2018-11-06 | 李莉 | 一种磷酸瑞卡帕布软胶囊及其制备方法 |
CN108976236B (zh) * | 2018-08-16 | 2020-11-10 | 湖南华腾制药有限公司 | 一种氘代parp抑制剂、其盐、其制备方法及用途 |
CN111217818A (zh) * | 2018-11-27 | 2020-06-02 | 台耀化学股份有限公司 | 芦卡帕尼樟脑磺酸盐的结晶、及制备三环化合物、芦卡帕尼及其樟脑磺酸盐结晶的方法 |
WO2020156577A1 (zh) * | 2019-02-02 | 2020-08-06 | 正大天晴药业集团股份有限公司 | 用于parp抑制剂的吲哚并七元酰肟类似物 |
CN110256468B (zh) * | 2019-05-14 | 2020-09-01 | 山东省分析测试中心 | 双吲哚生物碱化合物或其药学上可接受的盐及其制备方法和应用 |
WO2020229595A1 (en) | 2019-05-14 | 2020-11-19 | Molecular Targeted Radiopharmaceuticals Holding Gmbh (Mtr) | Quinazoline-2,4-dione derivatives as parp inhibitors |
AU2020311925A1 (en) | 2019-07-10 | 2022-02-03 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
WO2021007435A1 (en) | 2019-07-10 | 2021-01-14 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
CN114072410B (zh) * | 2019-08-01 | 2023-08-01 | 正大天晴药业集团股份有限公司 | 作为parp抑制剂吲哚并七元酰肟化合物 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
EP4100125A1 (de) | 2020-02-03 | 2022-12-14 | Sandoz AG | Polymorph von rucaparib-mesylat |
JP2023514794A (ja) | 2020-02-24 | 2023-04-10 | フーカン(シャンハイ) ヘルス テクノロジー カンパニー、 リミテッド | ポリadpリボースポリメラーゼ阻害剤の抗コロナウイルス応用 |
CN115485271A (zh) | 2020-04-28 | 2022-12-16 | 理森制药股份公司 | 用作聚(adp-核糖)聚合酶(parp)抑制剂的新型化合物 |
CN111646990B (zh) * | 2020-05-22 | 2023-01-10 | 同济大学 | 一种3,4-桥环吲哚类化合物的制备方法及Rucaparib的合成方法 |
CN111662299B (zh) * | 2020-07-10 | 2022-07-26 | 中山大学 | 一种取代吲哚并氮杂酮类化合物及其制备方法和应用 |
EP4182318A1 (de) | 2020-07-14 | 2023-05-24 | Assia Chemical Industries Ltd | Feste formen von rucaparibsalzen |
AU2021318572A1 (en) * | 2020-07-31 | 2023-02-16 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Indolo heptamyl oxime analog crystal as PARP inhibitor and method for preparing same |
CN111961047A (zh) * | 2020-08-19 | 2020-11-20 | 南通大学 | 一种6-乙氧基-3,4-二氢-2,7-萘啶-1(2h)-酮及其合成方法 |
WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
CA3207488A1 (en) | 2021-01-08 | 2022-07-14 | Cybrexa 2, Inc. | Process for preparing a conjugate linking moiety |
WO2022155172A1 (en) | 2021-01-13 | 2022-07-21 | Cybrexa 3, Inc. | Peptide conjugates of therapeutics |
IL307339A (en) | 2021-04-08 | 2023-11-01 | Rhizen Pharmaceuticals Ag | Poly(ADP-ribose) polymerase inhibitors |
EP4342898A1 (de) * | 2021-05-18 | 2024-03-27 | Onconic Therapeutics Inc. | Kristalline form einer tricyclischen derivatverbindung, verfahren zur herstellung davon und pharmazeutische zusammensetzung damit |
WO2023137060A1 (en) | 2022-01-11 | 2023-07-20 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib tosylate |
WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
WO2023233295A1 (en) | 2022-06-01 | 2023-12-07 | Ideaya Biosciences, Inc. | Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3642820A (en) | 1969-11-03 | 1972-02-15 | Upjohn Co | 4 5-dihydropyrrolo(3 2 1-jk)(1 4)bezodiazepines |
US3883590A (en) | 1971-06-01 | 1975-05-13 | Universal Oil Prod Co | Preparation of n-alkylarylcarboxamides |
DE2322434A1 (de) | 1973-05-04 | 1974-11-21 | Bayer Ag | 2-trifluormethylimino-1,3-dithioloeckige klammer auf 4,5-b eckige klammer zu -chinoxaline, verfahren zu ihrer herstellung, sowie ihre verwendung als insektizide, akarizide und fungizide |
US4033960A (en) | 1973-07-31 | 1977-07-05 | Bayer Aktiengesellschaft | 2-Mercaptoquinoxaline-di-N-oxide products and a method for their preparation |
US3950343A (en) | 1973-11-06 | 1976-04-13 | Ayerst, Mckenna And Harrison Ltd. | Pyrroloisoquinoline derivatives |
US3978066A (en) | 1973-11-06 | 1976-08-31 | Ayerst, Mckenna And Harrison Ltd. | Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives |
US3900477A (en) | 1973-11-06 | 1975-08-19 | Ayerst Mckenna & Harrison | 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives |
US3959343A (en) * | 1974-10-25 | 1976-05-25 | Wako Pure Chemical Industries, Ltd. | Process for producing hydrazonitriles |
DE2913728A1 (de) | 1979-04-05 | 1980-10-16 | Bayer Ag | 2-sulfonyl-chinoxaline, verfahren zu ihrer herstellung sowie ihre verwendung als mikrobizide |
DE3103137A1 (de) | 1981-01-30 | 1982-08-26 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung aliphatischer cyclischer kohlensaeureester |
JPS57144286A (en) | 1981-03-02 | 1982-09-06 | Takeda Chem Ind Ltd | Azepinoindole derivative and its preparation |
US5215738A (en) | 1985-05-03 | 1993-06-01 | Sri International | Benzamide and nicotinamide radiosensitizers |
US4910193A (en) | 1985-12-16 | 1990-03-20 | Sandoz Ltd. | Treatment of gastrointestinal disorders |
JPS6434988A (en) * | 1987-07-30 | 1989-02-06 | Kissei Pharmaceutical | Azepinoindole derivative |
DE4125292A1 (de) * | 1991-07-31 | 1993-02-04 | Kali Chemie Pharma Gmbh | 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
GB9117987D0 (en) | 1991-08-20 | 1991-10-09 | Ici Plc | Heterocyclic compounds |
US5342946A (en) | 1992-12-02 | 1994-08-30 | Guilford Pharmaceuticals Inc. | Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors |
AU674613B2 (en) | 1993-09-28 | 1997-01-02 | Otsuka Pharmaceutical Co., Ltd. | Quinoxaline derivative as antidiabetic agent |
US5587384A (en) | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
US5561161A (en) | 1994-03-25 | 1996-10-01 | Oxigene, Inc. | Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof |
US5589483A (en) | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
ES2105959B1 (es) | 1995-01-17 | 1998-07-01 | Zeneca Pharma Sa | Derivados de 1,4-dioxido de quinoxalina, procedimiento de preparacion y de utilizacion. |
US5756548A (en) | 1995-04-03 | 1998-05-26 | Centaur Pharmaceuticals, Inc. | Acetamidobenzamide compounds for neurodegenerative disorders |
US5659082A (en) | 1995-04-03 | 1997-08-19 | Centaur Pharmaceuticals, Inc. | Nitro- and aminobenzamide compounds for neurodegenerative disorders |
NZ313713A (en) * | 1995-08-02 | 2001-03-30 | Univ Newcastle Ventures Ltd | Benzimidazole-4-carboxamide derivatives useful as poly(ADP-ribose)polymerase or PARP enzyme inhibitors |
HUT76302A (en) | 1995-11-30 | 1997-07-28 | Chinoin Gyogyszer Es Vegyeszet | Quinoxaline derivatives, pharmaceutical compositions containing them and process for producing them |
US6028111A (en) | 1996-03-08 | 2000-02-22 | Oxigene, Inc. | Compositions and use of benzamides and nicotinamides as anti-inflammatory agents |
GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
AU745790B2 (en) | 1997-05-13 | 2002-03-28 | Octamer, Inc. | Methods for treating inflammation and inflammatory diseases using pADPRT inhibitors |
AU9298098A (en) | 1997-09-03 | 1999-03-22 | Guilford Pharmaceuticals Inc. | Amino-substituted compounds, methods, and compositions for inhibiting parp activity |
US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
WO1999011644A1 (en) | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
US20020022636A1 (en) | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
US20020028813A1 (en) | 1997-09-03 | 2002-03-07 | Paul F. Jackson | Thioalkyl compounds, methods, and compositions for inhibiting parp activity |
US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
AU9297998A (en) | 1998-05-15 | 1999-12-06 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, compositions, and methods for inhibiting parp activity |
JP2002515490A (ja) | 1998-05-15 | 2002-05-28 | ギルフォード ファーマシューティカルズ インコーポレイテッド | Parp活性を抑制する縮合三環化合物 |
HUP0104917A3 (en) | 1999-09-28 | 2002-12-28 | Basf Ag | Azepinoindole derivatives, the production and use thereof |
DE19946289A1 (de) | 1999-09-28 | 2001-03-29 | Basf Ag | Benzodiazepin-Derivate, deren Herstellung und Anwendung |
-
2000
- 2000-01-10 HU HU0105414A patent/HU229875B1/hu unknown
- 2000-01-10 TR TR2001/02005T patent/TR200102005T2/xx unknown
- 2000-01-10 GE GEAP20006045A patent/GEP20033055B/en unknown
- 2000-01-10 EP EP00902358A patent/EP1140936B1/de not_active Expired - Lifetime
- 2000-01-10 RO ROA200100795A patent/RO121778B1/ro unknown
- 2000-01-10 DK DK00902358T patent/DK1140936T3/da active
- 2000-01-10 AU AU24088/00A patent/AU781711B2/en not_active Expired
- 2000-01-10 SI SI200020013A patent/SI20691B/sl active Search and Examination
- 2000-01-10 EE EEP200100364A patent/EE05006B1/xx unknown
- 2000-01-10 PL PL357049A patent/PL210415B1/pl unknown
- 2000-01-10 NZ NZ512731A patent/NZ512731A/xx not_active IP Right Cessation
- 2000-01-10 WO PCT/US2000/000411 patent/WO2000042040A1/en active IP Right Grant
- 2000-01-10 DE DE60009033T patent/DE60009033T2/de not_active Expired - Lifetime
- 2000-01-10 JP JP2000593608A patent/JP4093448B2/ja not_active Expired - Lifetime
- 2000-01-10 EA EA200100764A patent/EA004989B1/ru not_active IP Right Cessation
- 2000-01-10 US US09/479,896 patent/US6495541B1/en not_active Expired - Lifetime
- 2000-01-10 MX MXPA01007001A patent/MXPA01007001A/es active IP Right Grant
- 2000-01-10 AT AT00902358T patent/ATE261963T1/de active
- 2000-01-10 CN CNB008045895A patent/CN100418967C/zh not_active Expired - Lifetime
- 2000-01-10 OA OA1200100183A patent/OA11749A/en unknown
- 2000-01-10 IL IL14411200A patent/IL144112A0/xx active IP Right Grant
- 2000-01-10 SK SK966-2001A patent/SK287338B6/sk not_active IP Right Cessation
- 2000-01-10 BR BRPI0008614A patent/BRPI0008614B8/pt not_active IP Right Cessation
- 2000-01-10 AP APAP/P/2001/002211A patent/AP1538A/en active
- 2000-01-10 ES ES00902358T patent/ES2218110T3/es not_active Expired - Lifetime
- 2000-01-10 KR KR1020017008709A patent/KR100632079B1/ko active IP Right Grant
- 2000-01-10 CA CA2360003A patent/CA2360003C/en not_active Expired - Lifetime
- 2000-01-10 CZ CZ20012443A patent/CZ302941B6/cs not_active IP Right Cessation
- 2000-01-10 PT PT00902358T patent/PT1140936E/pt unknown
- 2000-01-10 RS YUP-490/01A patent/RS50031B/sr unknown
- 2000-01-19 ID IDW00200101726A patent/ID30138A/id unknown
- 2000-10-01 UA UA2001074881A patent/UA75034C2/uk unknown
-
2001
- 2001-06-29 ZA ZA200105399A patent/ZA200105399B/en unknown
- 2001-07-02 IL IL144112A patent/IL144112A/en not_active IP Right Cessation
- 2001-07-04 NO NO20013313A patent/NO320343B1/no not_active IP Right Cessation
- 2001-07-10 IS IS5995A patent/IS5995A/is unknown
- 2001-07-30 HR HR20010573A patent/HRP20010573B1/xx not_active IP Right Cessation
- 2001-08-01 LV LV010115A patent/LV12770B/xx unknown
- 2001-08-10 LT LT2001083A patent/LT4936B/lt not_active IP Right Cessation
- 2001-08-10 BG BG105811A patent/BG65210B1/bg unknown
-
2002
- 2002-04-03 HK HK02102476A patent/HK1040992A1/xx not_active IP Right Cessation
- 2002-08-28 OA OA1200200262A patent/OA12185A/en unknown
- 2002-10-02 US US10/264,018 patent/US20030078254A1/en not_active Abandoned
-
2004
- 2004-12-03 US US11/004,261 patent/US6977298B2/en not_active Expired - Lifetime
-
2005
- 2005-09-06 US US11/221,245 patent/US7429578B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
OA11749A (en) | Tricyclic inhibitors of poly(adp-ribose)polymerases. | |
EP1208104B1 (de) | Trizyklische inhibitoren von poly(adp-ribose) polymerasen | |
CA2762226C (en) | Isoquinolin-1 (2h) -one derivatives as parp-1 inhibitors | |
WO2003106430A1 (en) | Benzimidazole inhibitors of poly(adp-ribosyl) polymerase | |
EP1899334A2 (de) | Naphthyridinverbindungen | |
TWI487707B (zh) | 3,4-二氫吡咯并[1,2-a]吡-2,8(1h)-二碳醯胺衍生物及其製備與治療用途 | |
JP2019536759A (ja) | 置換された二環式ヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤 | |
JP2015523352A (ja) | Katii阻害剤としての三環式化合物 |